However, we recently demonstrated that EPI-7386, an AR NTD small molecule inhibitor, inhibits AR activity by binding to Tau5 region of the NTD. In summary, we report preclinical data on the first generation of ANITAC molecules, that can be orally bioavailable and show activity against forms of AR expressed in late stage CRPC patients.

almost 3 years ago

Preclinical

AR (Androgen receptor)

AR expression • AR splice variant 7

masofaniten (EPI-7386) • EPI-8207